Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen

Abstract Background Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effe...

Full description

Bibliographic Details
Main Authors: Samuel Nkansah Darko, Henry Hanson, Sampson Twumasi-Ankrah, Sandra Baffour-Awuah, Priscilla Adjei-Kusi, Denis Yar, Ellis Owusu-Dabo
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-020-05053-z
id doaj-e2fc11b123fc4edf8d67e1bcef224db2
record_format Article
spelling doaj-e2fc11b123fc4edf8d67e1bcef224db22020-11-25T03:44:56ZengBMCBMC Infectious Diseases1471-23342020-05-012011910.1186/s12879-020-05053-zThree monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimenSamuel Nkansah Darko0Henry Hanson1Sampson Twumasi-Ankrah2Sandra Baffour-Awuah3Priscilla Adjei-Kusi4Denis Yar5Ellis Owusu-Dabo6Kumasi Centre for Collaborative Research in Tropical MedicineInfectious Disease Epidemiology Research Group, Kumasi Centre for Collaborative Research in Tropical MedicineDepartment of Mathematics, Kwame Nkrumah University of Science and TechnologyDepartment of Basic and Applied Biology, University of Energy and Renewable ResourcesInfectious Disease Epidemiology Research Group, Kumasi Centre for Collaborative Research in Tropical MedicineDepartment of Science Education, University of Education, WinnebaDepartment of Global and International Health, School of Public Health, Kwame Nkrumah University of Science and TechnologyAbstract Background Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. Methods A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. Results Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. Conclusion Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective.http://link.springer.com/article/10.1186/s12879-020-05053-zPraziquantelSchistosomiasisResistanceRenalUrinary
collection DOAJ
language English
format Article
sources DOAJ
author Samuel Nkansah Darko
Henry Hanson
Sampson Twumasi-Ankrah
Sandra Baffour-Awuah
Priscilla Adjei-Kusi
Denis Yar
Ellis Owusu-Dabo
spellingShingle Samuel Nkansah Darko
Henry Hanson
Sampson Twumasi-Ankrah
Sandra Baffour-Awuah
Priscilla Adjei-Kusi
Denis Yar
Ellis Owusu-Dabo
Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
BMC Infectious Diseases
Praziquantel
Schistosomiasis
Resistance
Renal
Urinary
author_facet Samuel Nkansah Darko
Henry Hanson
Sampson Twumasi-Ankrah
Sandra Baffour-Awuah
Priscilla Adjei-Kusi
Denis Yar
Ellis Owusu-Dabo
author_sort Samuel Nkansah Darko
title Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_short Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_full Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_fullStr Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_full_unstemmed Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_sort three monthly doses of 60 mg/kg praziquantel for schistosoma haematobium infection is a safe and effective treatment regimen
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2020-05-01
description Abstract Background Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. Methods A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. Results Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. Conclusion Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective.
topic Praziquantel
Schistosomiasis
Resistance
Renal
Urinary
url http://link.springer.com/article/10.1186/s12879-020-05053-z
work_keys_str_mv AT samuelnkansahdarko threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT henryhanson threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT sampsontwumasiankrah threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT sandrabaffourawuah threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT priscillaadjeikusi threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT denisyar threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT ellisowusudabo threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
_version_ 1724512623082340352